DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
email sent successfully
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Thyroid Eye Disease Candidate Proves Promising in Phase 1/2 Trial
Viridian Therapeutics Inc. this week announced positive topline clinical data from the third, low-dose cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED).
According to the company, the data validate the clinical activity of VRDN-001 and supports the proposed dosing interval for its VRDN-002 and VRDN-003 subcutaneous programs of up to once monthly.
“The rapid and meaningful improvements in signs and symptoms of TED observed with a low dose of VRDN-001 reinforce previously reported findings in this trial, and suggest that VRDN-001 may offer a differentiated efficacy profile,” Roger Turbin, MD, professor of Ophthalmology and Visual Science within the Department of Ophthalmology of Rutgers New Jersey Medical School, and an investigator on the VRDN-001 trial.
Evidence & EducationComparison of Two Different Regimens of Intravenous Methylprednisolone for Patients With Moderate to Severe and Acti...The intravenous methylprednisolone (iv M...
News & MeetingsDrug-Like Compound Stops Thyroid Overstimulation in Early NIH StudiesResearchers at the National Institutes o...
Evidence & EducationUnderstanding Unapproved use of Approved Drugs “Off Label” | U.S. Food & Drug AdministrationHas your healthcare provider ever talked...
News & MeetingsHorizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active ...Horizon Pharma plc today announced topli...
Evidence & EducationTeprotumumab for the Treatment of Active Thyroid Eye DiseaseBackground: Thyroid eye disease is a de...
Evidence & EducationEffects of Selenium on Short-Term Control of Hyperthyroidism due to Graves’ Disease Treated With Methimazole: ...Objective: In spite of previous conflic...
News & MeetingsA Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye DiseasePrior clinical trials of TEPEZZA(TM) hav...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.